The whole-genome sequencing of prospectively collected tissue biopsies from 442 patients with metastatic breast cancer reveals that, compared to primary breast cancer, tumor mutational burden doubles, the relative contributions of mutational signatures shift and the mutation frequency of six known driver genes increases in metastatic breast cancer. Significant associations with pretreatment are also observed. The contribution of mutational signature 17 is significantly enriched in patients pretreated with fluorouracil, taxanes, platinum and/or eribulin, whereas the de novo mutational signature I identified in this study is significantly associated with pretreatment containing platinum-based chemotherapy. Clinically relevant subgroups of tumors are identified, exhibiting either homologous recombination deficiency (13%), high tumor mutational burden (11%) or specific alterations (24%) linked to sensitivity to FDA-approved drugs. This study provides insights into the biology of metastatic breast cancer and identifies clinically useful genomic features for the future improvement of patient management.
B reast cancer is the most common malignancy among women worldwide 1 . In-depth analyses of primary breast cancer have provided clear evidence of clonal evolution and have resulted in the identification of a heterogeneous repertoire of nearly 100 disease-causing genes and passenger events, both resulting from various underlying mutational processes [2] [3] [4] [5] [6] including age-related deterioration, homologous recombination deficiency (HRD) 7 and apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) mutagenesis 8,9 . However, patients do not die from their primary breast tumor but as a consequence of metastases. Due to tumor evolution and treatment pressure, the genomic alterations in metastatic breast cancer can differ substantially from the primary tumor [10] [11] [12] [13] [14] [15] . Therefore, thorough genomic characterization of metastases will yield valuable insights into the active molecular processes in metastatic disease. This is crucial to understand the effects of systemic treatment on the tumor genome and ultimately improve the treatment of patients with metastatic breast cancer.
To date, in-depth analyses of metastatic breast cancer lesions are limited to studies using either whole-exome sequencing 16, 17 in relatively small cohorts or targeted sequencing of cancer-associated genes in a larger cohort 18 . These studies have suggested that metastatic breast cancer largely carries the same drivers seen in primary breast cancer; however, they also show clear differences in the numbers and types of genes that are affected.
To obtain an unbiased and complete picture of the genomic landscape of metastatic breast cancer and its underlying mutational processes, as reflected by mutational signatures, we performed whole-genome sequencing (WGS) on a large multicenter, prospective collection of snap-frozen metastatic tissue biopsies from 442 patients with breast cancer starting a new line of systemic treatment. These data enabled us to investigate the potential for patient-specific patterns of aberration that can be used to inform treatment choices. We performed an in-depth characterization of the genomic landscape of these patients with metastatic breast cancer and report on the presence of genomic alterations, and mutational and rearrangement signatures compared to a well-characterized cohort of primary breast cancer (the BASIS cohort) 6 . The available clinical data allowed us to associate genomic features with clinical information such as prior treatment. Finally, we identified subgroups of patients with specific and targetable genomic features who might be eligible for established or experimental therapies.
Results
The metastatic biopsies and matched germline DNA (peripheral blood) of 625 patients with metastatic breast cancer were analyzed ( Fig. 1a ). Patients with metastatic breast cancer whose primary tumor was biopsied (n = 55) were excluded from the metastatic analyses, but were used as an additional control group. Metastatic biopsy sites mainly included liver, lymph nodes, bone and soft tissue ( Fig. 1b ). Twenty-two percent of all metastatic biopsies could not be evaluated, while lesions obtained from bone metastases had a failure rate of 33% (Supplementary Table 1 ). Breast cancer subtype distribution did not differ between nonevaluable and evaluable biopsies. Metastatic tumor biopsies and paired normal samples from the remaining 442 patients were sequenced at a median read coverage of 107 (interquartile range (IQR) = 98-114) and 38 (IQR = 35-42), respectively.
The somatic landscape of metastatic breast cancer differs from primary breast cancer. Metastatic lesions showed a median of 7,661 single-nucleotide variants (SNVs; IQR = 4,607-14,417), 57 multiple-nucleotide variants (MNVs; IQR = 32-106), 689 small insertions and deletions (indels; IQR = 443-1,084) and 214 structural variants (SVs; IQR = 99-392 ( Supplementary Fig. 1) ). Estrogen receptor (ER) − tumors had a 1.6-fold higher SV count than ER + tumors (95% confidence interval (CI) 1.3-2.0, P < 0.001); human epidermal growth factor receptor 2 (HER2) + tumors had higher SV counts than HER2 − cases (P = 0.013).
Compared to the WGS from 560 primary breast cancer samples (BASIS cohort) 6 , the median numbers of SNVs, indels and SVs were significantly higher in metastatic breast cancer: 3,491 SNVs/MNVs (IQR = 2,075-6,911; 2.2×; 95% CI 1.9-2.4; P < 1 × 10 −5 ), 204 indels (IQR = 133-365; 3.3×; 95% CI 3.0-3.6; P < 1 × 10 −5 ) and 85 SVs (IQR = 25-208; 2.4×; 95% CI 2.1-2.8; P < 1 × 10 −5 ). Consequently, the median tumor mutational burden (TMB) of 2.97 per million base pairs (Mbp) (IQR = 1.84-5.44) in metastatic breast cancer was significantly higher than that observed in the BASIS primary breast cancer cohort (Supplementary Table 2 ) (1.29 per Mbp; IQR = 0.78-2.56; 2.2×, 95% CI 2.0-2.5; P < 1 × 10 −5 ). In line with our findings, another cohort of patients with metastatic breast cancer (Supplementary Table 2 ) also reported an elevated median TMB of 3.19 per Mbp (ref. 17 ). In our metastatic breast cancer cohort, we did not observe differences in median TMB between breast cancer subtypes and biopsy sites ( Supplementary Fig. 2 ).
To ensure that the higher TMB we observed in our metastatic breast cancer cohort compared to primary disease was not due to methodological differences (Supplementary Table 2 ), we used the data from the 55 patients in our cohort who were biopsied in their primary tumor ( Fig. 1a ), including 31 patients who were treatmentnaïve (group 1) and 24 patients who were pretreated (group 2). We compared the TMB of these primary tumors with the TMB of the metastatic biopsies of 61 patients who were treatment-naïve (group 3) and 369 patients who were pretreated (group 4) ( Supplementary  Fig. 3 ). In a multivariate linear regression model using these four groups, both type of tissue (metastatic/primary) and pretreatment (yes/no) were associated with TMB (P < 1 × 10 −5 for the model; the estimated coefficients were 0.3212 (P = 0.02) and 0.3664 (P = 0.001), respectively). After stratifying for ER status, both pretreatment (0.4404, P = 0.014) and type of tissue (0.5208, P = 0.0003) were associated with TMB in ER + cases but not in ER − cases. However, low numbers (only eight pretreated primary ER − tumors) make the interpretation of the results of this regression inconclusive. This suggests that, next to disease course, treatment pressure is a major contributor to TMB.
Mutational signatures are associated with pretreatment. To investigate which mutational processes operate in metastatic breast cancer and to what extent pretreatment is associated with the resulting mutational patterns, we applied the mathematical approach proposed by Alexandrov et al. 2 Fig. 2a and Supplementary Fig. 4 ). Except for de novo signatures I and J, all identified signatures have been previously described in primary breast cancer. De novo signature J was very similar to COSMIC mutational signature 7, which is probably due to ultraviolet (UV) exposure. Detailed evaluation showed that the algorithm only identified this signature in one patient with a very high contribution (>98%), suggesting that this liver biopsy, containing mostly UV-induced DNA damage, had been misclassified as metastatic breast cancer.
De novo signature I (221 patients with >10% contribution, 27 patients with >25% contribution) was very similar to COSMIC mutational signatures 4 and 8 ( Fig. 2b) and was more frequently observed in patients pretreated with platinum-based chemotherapy (P = 0.001) in our cohort. Signature 4 has been associated with tobacco mutagens 15 and is characterized by C>A substitutions and CC>AA dinucleotide substitutions 5 . The etiology of signature 8 is still unknown but its presence has been observed in primary breast cancer and was recently linked to BRCA deficiency 7 . This signature also shows C>A substitutions and has the CC>AA characteristic. Cisplatin mainly forms Pt-d(GpG) di-adducts 16 and patients pretreated with platinum-based chemotherapy showed higher levels of CC>AA substitutions (1.8×, 95% CI 1.2-2.5; P = 0.0013) than patients who did not receive platinum treatment. Also, patients with at least a 10% contribution of de novo signature I had higher levels of CC>AA (2×, 95% CI 1.6-2.2; P < 1 × 10 −5 ; Fig. 2c ), but patients 19 and samples of patients who did (n = 43) or did not (n = 385) receive prior treatment with platinum-based chemotherapy. e, Box plot of the contribution of mutational signature I and samples with a high (permutation P < 0.05, n = 59) or low (permutation P > 0.05, n = 383) similarity to the cisplatin signature identified by Boot et al. 19 . The red dots indicate samples with >25% contribution of de novo signature I. c-e, The box is bounded by the 25th and 75th percentiles, with the horizontal line in the box depicting the median. The whiskers extend to 1.5 of the IQR above the 75th and below the 25th percentiles.
with at least a 10% contribution of signature 8 did not have elevated CC>AA levels (P = 0.706). A previously published cisplatin signature 19 with characteristic C>T conversion peaks, which are absent in de novo signature I, had a higher cosine similarity in patients pretreated with platinum-based chemotherapy than in patients who did not receive this pretreatment (1.2×, 95% CI 1.1-1.3; P = 0.0008; Fig. 2d ). Furthermore, when samples were dichotomized in two groups based on their similarity to the cisplatin signature identified by Boot et al. 19 (permutations P < 0.05 and P > 0.05, respectively), 23 out of 27 samples with at least 25% contribution of de novo signature I had a high similarity to this signature (2.6×, 95% CI 2.4-3.0; P < 1 × 10 −5 ; Fig. 2e ). Next, since de novo signature I resembles signature 8, which in turn is linked to BRCA deficiency 7 , we analyzed germline BRCA mutation status in this context. A multivariate regression model showed that both germline BRCA mutation status and pretreatment with platinum-containing drugs were significantly associated with the relative contribution of de novo signature I (P < 1 × 10 −5 for the model; estimated coefficients for germline BRCA mutation status 10.36 (P = 5.4 × 10 −7 ) and 4.13 (P = 0.0014) for pretreatment with platinum). Since the observed de novo signatures largely overlapped known COSMIC signatures, we also determined the contributions of these 30 known signatures to the mutational landscape of our cohort (Supplementary Figs. 5 and 6). Out of the 30 COSMIC signatures, 12 contributed to ≥10% of the observed mutations in at least 5 patients; therefore, they were defined as dominant signatures (Fig. 3 ). The most frequently represented signatures in metastatic breast cancer were signature 8 (64% of patients), signature 1 (59%), which is related to aging, signatures 2 (43%) and 13 (36%), which are related to APOBEC mutagenesis, and signature 3 (41%), which is associated with HRD. Analyses according to breast cancer subtype revealed that signatures 3 and 9 mutations were significantly more often present (2.7×, 95% CI 1.9-3.9 and 1.3×, 95% CI 1.1-1.6, respectively) in ER − compared to ER + metastatic breast cancer, whereas signature 2 (APOBEC) mutations were significantly more frequent (2.1×; 95% CI 1.5-2.9) in ER + metastatic breast cancer (all P < 0.05).
Ten of the 12 COSMIC signatures detected in our metastatic breast cancer cohort were previously described in the BASIS primary breast cancer cohort 6 (signatures 1-3, 5, 6, 8, 13, 17, 18 and 30), whereas signatures 9 (8%) and 16 (14%) were not reported in the BASIS cohort 6 . After reevaluation of the previously published BASIS data 6 , we found that the latter two signatures were actually present, but at relatively low levels (median relative contribution <5%). Subsequently, we compared the absolute and relative contributions of the 12 dominant COSMIC signatures between our metastatic breast cancer cohort and the BASIS primary breast cancer cohort per breast cancer subtype ( Fig. 3 ; see Supplementary  Fig. 5 for all relative comparisons of the 30 COSMIC signatures). Irrespective of breast cancer subtype, the median absolute number of mutations was higher in metastatic breast cancer compared to primary breast cancer for almost all signatures ( Supplementary  Fig. 6 ), reflecting the significantly higher TMB in metastatic breast cancer and ongoing mutagenic processes.
On a relative scale, we found a decrease in signatures 1 and 5 (age) and signature 16 (reported in liver cancer), as well as an increase in signatures 2 and 13 (APOBEC) and signature 17 (unknown etiology) in ER + /HER2 − metastatic disease compared to ER + /HER2 − primary breast cancer from the BASIS cohort. In triplenegative breast cancer (TNBC), a decrease in signature 3 (HRD) and an increase in signatures 2 and 17 was seen in metastatic lesions compared to primary breast cancer. In patients with HER2 + disease, no differences in the relative contributions of the 12 dominant signatures were found between primary and metastatic disease ( Fig. 3 ), irrespective of taking ER status into account.
To determine whether these differences between primary breast cancer and metastatic breast cancer were driven by disease course or pretreatment, we performed a multivariate linear regression analysis using the previously defined four groups of primary and metastatic lesions with and without pretreatment. This showed a significantly lower (signature 1) and higher (signature 17) contribution in patients who were pretreated, irrespective of disease course. Thus, pretreatment in itself-regardless of treatment type-causes a limited shift in certain signature patterns.
Within metastatic breast cancer lesions, we also investigated the potential role of specific pretreatments on the relative signature contributions for all 12 dominant COSMIC signatures as defined earlier. Pretreatment with fluorouracil (5-FU), taxanes, platinumcontaining chemotherapy and/or eribulin was associated with significantly higher relative contributions of signature 17 (all false discovery rate (FDR) P values < 0.05, with 5-FU the most significant at an FDR P value = 2.0 × 10 −9 ) ( Supplementary Fig. 7 ). These treatments had been given to 40, 58, 10 and 3% of patients, respectively. The large overlap in patients who were pretreated with all or combinations of these therapies hampered further specification of which of these therapies is directly associated with signature 17. Although signature 17 is present in primary breast cancer due to endogenous processes, the fact that signature 17 is mainly characterized by T>G and T>C in a CTT context might implicate 5-FU, which inhibits thymidylate synthase and thus synthesis of thymidine 20 , as a probable drug contributing to this pattern. Finally, we investigated the association between mutational signatures and response to the line of therapy that was initiated directly after sampling tumor material. Patients with progression at first response evaluation after 12 weeks of treatment had a significantly higher relative contribution of signature 17 (P = 0.0012). However, we also observed that the number of pretreatments given was higher in patients with ≥10% signature 17 contribution, making it hard to distinguish whether or not signature 17 is truly a biomarker for poor response to therapy or a marker of poor outcome in general.
In conclusion, virtually all mutational processes present in primary breast cancer contribute to the observed increased TMB in metastatic breast cancer. On a relative scale, we observed a shift from more indolent age-related mutagenesis in primary disease toward more APOBEC-driven processes in metastatic breast cancer. Additionally, previously given lines of therapy can impose specific mutational profiles in breast cancer cells.
Structural variation and HRD. To evaluate structural variation in metastatic lesions, we extracted the six rearrangement signatures described previously 6 . Rearrangement signatures 1 and 3 (SV1 and SV3) were the least prevalent (both 6% of all rearrangements) in metastatic lesions while SV2, SV4 and SV6 contributed 20, 14 and 19%, respectively. SV5 was the most dominant and contributed to 36% of all rearrangements. Compared to primary breast cancer, the relative contribution of SV3, related to BRCA1 gene abrogation, was significantly decreased (2.9×; 95% CI 1.5-7.1; P < 1 × 10 −5 ) while BRCA2-related SV5 increased (3.2×; 95% CI 2.7-3.8; P < 1 × 10 −5 ) in metastatic lesions regardless of breast cancer subtype ( Supplementary Fig. 8 ).
To investigate the presence of an HRD phenotype based on somatic alterations, we applied the recently developed Classifier of Homologous Recombination Deficiency (CHORD) (L.N., A.v.H. and E.C., manuscript in preparation). This algorithm predicts HRD and assigns the BRCA gene most probably responsible based on a combination of rearrangement signatures (SV1, SV3 and SV5), a specific type of indels flanked by microhomology and mutational signature 3. In our cohort of 442 patients, 18 had a germline loss of BRCA1 or 2 (BRCA1, n = 5; BRCA2, n = 13). CHORD identified 39 additional patients carrying an HRD tumor next to all 18 germline BRCA mutation carriers.
Unsupervised clustering reveals eight distinct genomic clusters in metastatic breast cancer. Based on the genomic characteristics of our metastatic breast cancer cohort comprising 442 metastatic lesions, we performed an unsupervised clustering analysis, which revealed 8 clusters representing tumors with distinct genomic phenotypes ( Fig. 4) . Biopsy site and treatment outcome were evenly distributed among the eight clusters. Clusters A and B were both characterized by mutational signature 3. Cluster A was further characterized by short tandem duplications and by SV3; cluster B was characterized by large deletions and SV5. In addition, these two clusters were enriched for HRD (P < 1 × 10 −5 ) as predicted by the CHORD algorithm. In cluster A, HRD was predicted to be based on BRCA1 deficiency; in cluster B, it was predicted to be based on BRCA2 deficiency. However, clusters A and B also contained one and four patients, respectively, who were predicted to be homologous recombination-proficient. In these patients, we checked for mutated genes that are known in HR (as described in the Methods); however, none of these genes were homozygously affected.
Clusters C, D and E were characterized by mutational signatures 17, 18 and 16, respectively. Cluster F was mainly based on insertions. Cluster G showed a low TMB, few SVs and a relatively high proportion of mutational signature 5. Finally, cluster H represented tumors predominantly harboring mutational signatures 2 and 13 related to APOBEC mutagenesis, a relatively high TMB and kataegic events.
Kataegis was observed in 177 (40%) patients with metastatic breast cancer (ranging from 1 to 144 events), with 15 patients exhibiting 10 or more foci. In kataegic foci, mainly APOBEC-mediated mutagenesis occurred (P < 0.001; Supplementary Fig. 9 ). Patients exhibiting kataegis frequently harbored ATR mutations (21 out of 25 identified patients with an ATR mutation showed kataegis), suggesting that kataegis might be associated with collapsing replication forks in these patients.
Somatic drivers of metastatic breast cancer: SNVs and copy number alterations. Using the ratio of nonsynonymous and synonymous mutations (dN/dScv) 21 , we identified 21 potential driver genes, including known key drivers of breast cancer. The top five driver genes were TP53 (42.8%), PIK3CA (42.3%), ESR1 (14.3%), GATA3 (11.3%) and KMT2C (11.3%) ( Supplementary  Fig. 10 ). With regard to breast cancer subtypes, TP53 was enriched in TNBC (P < 1 × 10 −5 ), whereas ESR1, PIK3CA and GATA3 were more often mutated in ER + metastatic breast cancer (all P < 0.001). ESR1 mutations were, as expected, more frequently present in patients pretreated with aromatase inhibitors (26.9% in patients who were pretreated versus 2.7% in patients without aromatase inhibitor pretreatment).
In addition to nonsynonymous mutations, we observed 44 rearrangements involving ESR1 in 34 patients and deep gains of ESR1 in 29 patients. Fusions, mutations and deep gains were not mutually exclusive, but were specific to ER + breast cancer. No amplifications of cis-acting enhancers of ESR1 were observed.
We compared the frequency of alterations in our 21 identified potential drivers in metastatic breast cancer with two primary breast cancer cohorts: The Cancer Genome Atlas (TCGA) 4 and BASIS 6 cohorts ( Fig. 5 ). Using an FDR < 0.05, the six genes ESR1, TP53, NF1, AKT1, KMT2C and PTEN (Table 1 and Supplementary Table 3 ) were more frequently mutated in ER + /HER2 − metastatic lesions than in primary breast cancer. Except for ESR1, these genes were not associated with pretreatment, nor with response. Individual analysis did not reveal mutual exclusivity of these genes; however, grouping of mitogen-activated protein kinase pathway and ER transcriptional regulator genes (NF1, TBX3, ERBB2, CTCF, EGFR, KRAS, BRAF, ERBB3, HRAS, MYC) showed mutual exclusivity with ESR1, as shown by Razavi et al. 18 . In patients with HER2 + disease (irrespective of subdivision by ER status) or TNBC, no significant differences were observed. A bootstrap analysis to better estimate the distribution of gene mutation frequencies in primary disease (TCGA and BASIS cohorts combined) confirmed that the observed enrichments of ESR1, TP53, NF1, AKT1, KMT2C and PTEN mutations were unlikely to be explained by sampling bias.
The dN/dScv analysis identified an additional potential driver gene, GPS2, which was not identified as a driver gene in primary breast cancer 6 , but was recently described by Martincorena et al. 21 in primary breast cancer. The GPS2 protein forms a complex with NCOR1 and HDAC3. The three genes encoding these proteins were affected in an almost mutually exclusive fashion; 35 out of 36 patients harboring mutations in these genes had only one gene affected (CoMEt exact test, P < 1 × 10 −5 ), indicating that the loss of either gene in this complex is sufficient. Alterations in the GPS2-NCOR1-HDAC3 complex are enriched in metastatic breast cancer compared to primary breast cancer (P = 0.004), but not associated with a specific prior treatment or breast cancer subtype.
Regarding the 93 primary breast cancer driver genes reported by Nik-Zainal et al. 6 , we found that, in addition to the differences between ER + /HER2 − primary and metastatic disease for ESR1, NF1 and TP53 mutations, KMT2D was also more frequently affected in metastatic disease whereas AXIN1 was less frequently altered compared to primary breast cancer (FDR < 0.05) ( Supplementary Table  4 ). Again, no differences for HER2 + (irrespective of subdivision by ER status) and TNBC were observed.
Copy number analyses identified 51 narrow regions with somatic copy number alterations, including amplification peaks containing known driver genes such as ERBB2, MYC and CCND1 and deletion peaks containing known tumor suppressor genes such as PTEN, CDKN2A, RB1 and NF1. Using an FDR < 0.05, 29 regions were associated with ER status, that is, MYC, SLC1A2 and HOOK3 were more frequently amplified in ER − metastatic breast cancer and PLK2 was more frequently deleted in ER − metastatic breast cancer. All amplification and deletion peaks in relation to ER status are shown in Supplementary Table 5 . The total number of copy number alterations within these 51 regions was not associated with metastatic site or prognosis after 12 weeks of treatment. In addition we observed 6 focal amplification peaks (<5 kilobases (kb)) in noncoding parts near three known breast cancer driver genes-ZNF217, ZNF703 and MYC-and three other genes LINC00266-1, TRPS1 and KCNMB2.
Potential clinical implications of WGS.
To evaluate whether WGS may be used to improve treatment choices for future patients with metastatic breast cancer, we specifically focused on (1) high TMB/microsatellite instability (MSI) as a potential biomarker to select patients for immunotherapy, (2) HRD for poly-ADP ribose polymerase inhibitors and/or double-stranded DNA break-inducing chemotherapy and (3) specific genomic alterations for which Food and Drug Administration (FDA)-approved drugs are already available (Fig. 6) .
Using a threshold of ≥10 mutations per Mbp in our cohort, previously used to distinguish patients whose lung cancer responded to nivolumab plus ipilimumab from those whose did not 22 , we identified 50 patients (11%) in our cohort with a high TMB, which, in most patients (70%), could be largely attributed to APOBEC-related mutations (≥50% of all mutations). In primary breast cancer, APOBEC mutagenesis was previously associated with the presence of tumor-infiltrating lymphocytes further confirming the antigenicity of APOBEC mutant cancers 23, 24 . High TMB was not associated with breast cancer subtype, suggesting that inclusion of patients into future clinical trials investigating checkpoint inhibitors should potentially be based on their genomic landscape rather than on tumor subtype ( Supplementary Fig. 2a ). Notably, five patients had a high TMB and a mutation in either JAK2 or STAT3. As these latter mutations could help evade the native immune response, this might be of clinical relevance as well 25 . We also identified 7 (1.5%) patients with MSI according to MSI-seq 26, 27 , which is currently not tested in standard care but for which pembrolizumab has been approved for use in all tumor types 28 .
Using CHORD, we identified 39 additional patients with HRD (9%) who did not harbor germline alterations in BRCA1 or BRCA2. Based on their HRD phenotype, these patients might benefit from poly-ADP ribose polymerase inhibitors and/or chemotherapeutic agents that induce double-stranded DNA breaks 29 .
Finally, we analyzed which patients could be treated with FDAapproved drugs based on the alterations present in their genome using the clinical annotation database OncoKB 30 . One hundred and five patients (24%) had at least one actionable event for which an FDA-approved drug is currently available; 67 (15%) of all patients had an ERBB2 amplification, 7 of whom had tumors that were clinically identified as HER2 − . These patients might benefit from anti-HER2 therapies, which are already approved for breast cancer. Additionally, 47 patients had at least 1 alteration predicting response to a drug registered for other tumor types than breast cancer ( Fig. 6 and Supplementary Table 6 ). In summary, WGS provides us with a valuable tool to determine clinically relevant molecular features for informed treatment choices, such as TMB, HRD, MSI and actionable mutations in one assay.
Discussion
An important feature of the current study is that all patients starting a new line of systemic treatment could participate. Thus, our cohort consists of patients treated with a heterogeneous repertoire of treatments leading to large differences in progression-free and overall survival. Expanding the number of patients combined with the registration of already known clinical prognostic factors, such as clinical performance scores and number of metastatic sites, allows for future reliable association analyses between genomic alterations and outcome stratified according to relevant patient characteristics including pretreatment, breast cancer subtype and line of treatment.
We have identified differences in metastatic breast cancer compared to primary breast cancer regarding TMB, the frequency in which driver genes are affected and the relative contribution of mutational signatures. Moreover, we have shown that the use of WGS enables to identify subgroups of patients (42% of all patients with metastatic breast cancer) for personalized treatment. Therefore, future clinical trials should incorporate tissue biopsies for sequencing and base treatment stratification on 'clinical genomics' .
Based on the current knowledge and treatment armamentarium, we still have a substantial number of patients with metastatic breast cancer (58%) without currently known targetable genomic features. Further exploration of large copy number changes, specific combinations of mutated genes and RNA sequencing will potentially unravel new actionable targets or profiles. The development and approval of new drugs that are currently under investigation, such as phosphoinositide 3-kinase inhibitors potentially relevant to a large subset of patients with metastatic breast cancer (42% harbor a PIK3CA mutation in our cohort), will further increase the targetability of the tumor's genome.
Overall, our study provides substantial insight into the biology of metastatic breast cancer and generates useful genomic information for future improvement of patient management.
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Methods
Patient cohort and study procedures. For our analyses, we selected patients with metastatic breast cancer who were included under the protocol of the Center for Personalized Cancer Treatment (CPCT) consortium (CPCT-02 Biopsy Protocol, ClinicalTrial.gov no. NCT01855477), which was approved by the medical ethics committee of the University Medical Center Utrecht, the Netherlands. A detailed description of the consortium and whole patient cohort has been described in detail recently 27 . The consortium consists of 49 oncology centers in the Netherlands and aims to analyze the cancer genome of patients with advanced cancer, irrespective of cancer type, to develop predictors for outcome to systemic treatment. Patients ≥18-years-old with incurable locally advanced or metastatic solid tumors, for whom a histological biopsy could be safely obtained and systemic treatment with anticancer agents was indicated, were eligible for inclusion. All patients gave written informed consent before any study procedure; the study complies with all relevant ethical regulations. We performed an in-depth analysis of all included patients with metastatic breast cancer. Patients whose primary breast tumor was biopsied (n = 55) were excluded from the metastasis analyses, but were used as an additional control group. Patients with evaluable biopsies were classified according to ER and HER2 status (Supplementary Table 1 ). Collection and sequencing of samples was performed as described previously 27 .
Treatment outcome. Clinical outcome was evaluated according to RECIST v.1.1 after 12 weeks of treatment and was defined as stable disease, partial response, complete response or progressive disease 31 . To relate outcome to genomic data, we defined response to therapy as complete or partial response after 12 weeks of treatment and nonresponse as progressive disease after 12 weeks of treatment.
Detection of somatic changes.
Detailed methods on calling somatic SNVs, MNVs and SVs were described previously 27 . Additional annotation of somatic variants and heuristic filtering was performed. Heuristic filtering removed somatic SNV, indel and MNV variants based on the following criteria: (1) minimal alternative read observations ≤3; (2) Genome Aggregation Database (gnoMAD) exome (all) allele frequency ≥0.001 (corresponding to approximately 62 gnoMAD individuals); and (3) gnoMAD genome (ALL) ≥0.005 (approximately 75 gnoMAD individuals) 32 .
GnoMAD v.2.0.2 was used. When multiple variants at the same genomic position were present, the most deleterious mutation was used to annotate the overlapping gene. SVs with a B-allele frequency ≥0.1 were further annotated by retrieving overlapping and nearest upstream and downstream annotations using custom R scripts based on the GRCh37 canonical University of California, Santa Cruz (UCSC) promoter and gene annotations with regard to their respective upstream or downstream orientation (if known) 33 . Only potential fusions with two different gene partners were considered; SVs with both breakpoints falling within the same gene were simply annotated as SV mutations. Fusion annotation from the COSMIC (v.85), Cancer Genome Interpreter (CGI, accessed 6 November 2018) and Clinical Interpretation of Variants in Cancer (CIViC, accessed 6 November 2018) databases were used to assess known fusions [34] [35] [36] . The COSMIC, OncoKB (accessed 12 July 2018), CIViC (accessed 6 November 2018) and CGI (accessed 6 November 2018) databases and the list from Martincorena et al. 21 (dN/dS) were used to classify known oncogenic or cancer-associated genes [34] [35] [36] .
Ploidy and copy number analysis. Ploidy and copy number analysis was performed using a custom pipeline as described previously 27 . Briefly, this pipeline combines B-allele frequency, read depth and SVs to estimate the purity and copy number profile of a tumor sample. Recurrent focal and broad copy number alterations were identified with GISTIC v.2.0.23 (ref. 37 ). GISTIC was run with the following parameters: genegistic 1; gcm extreme; maxseg 4000; broad 1; brlen 0.98; conf 0.95; rx 0; cap 3; saveseg 0; armpeel 1; smallmem 0; res 0.01; ta 0.1; td 0.1; savedata 0; savegene 1; and qvt 0.1. Categorization of shallow and deep copy number aberration per gene was based on thresholded GISTIC calls. Focal peaks detected by GISTIC were re-annotated based on overlapping genomic coordinates, using custom R scripts and UCSC gene annotations. GISTIC peaks were annotated with all overlapping canonical UCSC genes within the narrow peak limits. If a narrow GISTIC peak overlapped with ≤3 genes, the most probably targeted gene was selected based on oncogenic or tumor suppressor annotation in the COSMIC, OncoKB, CIViC and CGI lists 21, [34] [35] [36] . Peaks in gene deserts were annotated with their nearest gene.
Putative enhancer regions (as detected by GISTIC; focal amplification peaks with a width <5,000 bp) were retrieved per sample. If regions overlapped multiple distinct copy number segments, the maximum copy number value of the overlapping segments was used to represent the region. Samples with geneto-enhancer ratios deviating by >1 studentized residual from equal 1:1 gene-toenhancer ratios (linear model: log 2 (copy number of enhancer) − log 2 (copy number of gene locus) = approximately 0) were categorized as gene-or enhancer-enriched. Based on the direction of the ratio, samples were either denoted as enhancer-(if the ratio was positive) or gene-enriched (if the ratio was negative).
Estimation of TMB. The mutation rate per million base pairs (Mbp) of genomic DNA was calculated as the total genome-wide amount of SNVs, MNVs and indels divided by the total amount of mappable nucleotides (ACTG) in the human reference genome (hg19) FASTA sequence file:
The mutation rate per Mb of coding mutations was calculated as the amount of coding SNVs, MNVs and indels divided by the summed lengths of distinct nonoverlapping coding regions, as determined on the subset of proteincoding and fully supported (transcript support level (TSL) = 1) transcripts in GENCODE v.28 (hg19): 38
MSI and HRD prediction. HRD/'BRCAness' was estimated using the CHORD classifier. This classifier was based on the HRDetect 7 algorithm; however, it was redesigned to improve its performance beyond primary breast cancer. The binary prediction score (ranging from 0 to 1) was used to indicate the BRCAness level within a sample. A BRCA1/2 variant was assigned as pathogenic when annotated by ENIGMA 39 (accessed 26 February 2018) or ClinVar 40 (accessed 28 January 2018). We used the following gene list to check whether homologous recombinationrelated genes were mutated in samples that clustered in clusters A and B and were classified as homologous recombination-proficient ( Fig. 4 ): ATM; BARD1; BLM; BRCA1; BRCA2; BRIP1; EME1; ERCC1; ERCC4; EXO1; GEN1; H2AFX; MRE11/MRE11A; MUS81; NBN; NSMCE1; NSMCE2; PALB2; PCNA; RAD18; RAD21; RAD50; RAD51; RAD51AP1; RAD51C; RAD51L1; RAD51L3; RAD52; RAD54B; RAD54L; RECQL4; RECQL5; RTEL1; SLX1A; SLX4; TDP1; WRN; XRCC2; and XRCC3.
MSI status was determined using the MSI-seq score 26, 27 . Briefly, this validated score classifies a sample based on the number of indels per Mbp occurring in homopolymers of ≥5 bases or dinucleotide, trinucleotide and tetranucleotide sequences with a repeat count ≥4. A sample with an MSI-seq score ≥4 was considered MSI. Detection of (onco)genes under selective pressure. To detect (onco)genes under tumor evolutionary mutational selection, we employed a Poisson-based dN/dS model (under the full trinucleotide model; 192 rate parameters) using the R package dndscv v.0.0.0.9 (ref. 21 ). Briefly, this model tests the normalized ratio of nonsynonymous (missense, nonsense and splicing) over background (synonymous) mutations while correcting for sequence composition and mutational signatures. A global q ≤ 0.1 (with and without taking indels into consideration) was used to identify statistically significant driver genes.
Identification of hypermutated foci (kataegis).
Putative kataegic events were detected using a dynamic programming algorithm that determines a globally optimal fit of a piecewise constant expression profile along genomic coordinates as described by Huber et al. 41 and implemented in the tilingArray R package v.1.56.0. Only SNVs were used to detect kataegis. Each chromosome was assessed separately and the maximum number of segmental breakpoints was based on a maximum of 5 consecutive SNVs (maximum 5,000 segments per chromosome). Fitting was performed on log 10 -transformed intermutational distances. Per segment, we assessed if the mean intermutational distance was ≤2,000 bp and at least 5 SNVs were used in the generation of the segment. Samples with >200 distinct observed events were set to zero-observed events since these were hypermutated throughout the entire genome rather than locally. Kataegis was visualized using the R package karyoploteR v.1.4.1 (ref. 42 ).
Mutational and structural rearrangement signature analysis. Mutational signature analysis using the MutationalPatterns R package v.1.4.2 was performed as described previously 43 . The thirty COSMIC mutational signatures, as established by Alexandrov et al. 2 (matrix Sij; i = 96 trinucleotide motifs; j = number of signatures) were downloaded from COSMIC (accessed on 23 May 2018). For de novo signature calling, between 2 and 20 signatures were assessed using the NMF package v.0.21.0 with 500 iterations 44 . By comparing the cophenetic correlation coefficient over the range of possible signatures, we opted to assign ten de novo signatures. We used the cosine similarity metric to compare de novo with COSMIC signatures. Structural rearrangement signatures were established as described previously 6 . Briefly, SVs were called using Manta v.1.0.3 (ref. 45 ) and default parameters, after which additional filters were applied 27 . The reported tandem duplications, deletions, inversions, insertions and translocations were then categorized by size (<10 kb, 10-100 kb, 100 kb-1 Mb, 1-10 Mb and >10 Mb). Interrearrangement distances were calculated and rearrangements were labeled as clustered if the average interrearrangement distance of a segment was at least ten times less than the whole-genome average for a patient sample. The segments were determined using a piecewise constant fitting function ('exactPcf ' from the copynumber R package) using a minimum of ten events in a segment (K min ) and 1 nature research | reporting summary Last updated by author(s): Aug 2, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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Sample size
Data from all available metastatic breast cancer patients were requested, without performing sample-size calculation. For proportional comparisons (i.e. frequencies between primary breast cancer (BC) en metastatic breast cancer (MBC)) we can detect the following mutation increases in the total cohort and subgroups with 80% power and alpha = 0.05, assuming a 5% mutation frequency in the primary cohort: 
